Novapio (Metformin Hydrochloride, Pioglitazone)

Metformin Hydrochloride and Pioglitazone, the active ingredients in Novapio, are a biguanide and thiazolidinedione presented as oral tablets for oral use. They are indicated for the management of type 2 diabetes mellitus in adult patients. Both agents work synergistically to lower blood glucose by targeting hepatic production and peripheral insulin sensitivity, offering a comprehensive approach to glycaemic control.

GNH USA supplies Novapio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics to ensure product integrity across global markets.

Novapio combines metformin and pioglitazone to improve glycaemic control in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Insulin resistance: enhances peripheral insulin sensitivity in muscle and adipose tissue. - Hyperglycemia: reduces hepatic glucose output to achieve target HbA1c.

Novapio may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild stomach upset, often transient. - Diarrhea: loose stools, may lead to dehydration. - Abdominal discomfort: cramping or bloating. - Headache: mild to moderate intensity. - Weight gain: gradual increase, especially with pioglitazone. - Edema: peripheral swelling, commonly ankles.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic acidosis. - Congestive heart failure exacerbation: fluid retention leading to dyspnea. - Hepatotoxicity: elevated liver enzymes or liver injury. - Severe hypoglycaemia: especially when combined with insulin or sulfonylureas. - Bone fracture: increased risk with long‑term pioglitazone use. - Bladder cancer: potential increased risk with prolonged therapy.

When prescribing Novapio, clinicians should consider several safety precautions to minimise risk.

- Renal function: assess eGFR before initiation and periodically, as metformin accumulation can occur. - Hepatic function: evaluate liver enzymes, since pioglitazone may affect hepatic metabolism. - Cardiovascular status: monitor for signs of heart failure or edema, particularly in patients with existing cardiac disease. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; data are limited. - Concomitant medications: review for drugs that may increase metformin levels or affect pioglitazone metabolism. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Novapio can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure, contraindicating metformin use. - Strong CYP2C8 inhibitors (e.g., gemfibrozil): increase pioglitazone plasma concentrations, raising toxicity risk. - Insulin or sulfonylureas: combined therapy can cause severe hypoglycaemia. - Cimetidine: may reduce metformin renal clearance, increasing plasma levels. - Diuretics with thiazide component: exacerbate fluid retention and edema.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium when used together. - NSAIDs: can impair renal function, affecting metformin excretion. - Oral contraceptives: may slightly increase metformin levels. - Alcohol: enhances risk of lactic acidosis, especially with metformin.